NCT03909334 2026-04-17
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Hoosier Cancer Research Network
Phase 2 Active not recruiting
Clinical Trials
20 trialsNCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03081143 2026-04-14
RAMIRIS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Active not recruiting
NCT04310007 2026-04-13
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05980000 2026-03-31
Rambro2
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT04340882 2026-01-30
DoceRamPem
Emory University
Phase 2 Active not recruiting
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03527108 2026-01-14
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT03650764 2025-12-30
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT04145349 2025-12-08
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT05002127 2025-08-07
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology Inc.
Phase 2/3 Active not recruiting
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT02678182 2025-06-10
PLATFORM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT05096663 2025-05-15
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT06542731 2024-08-07
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT03760822 2024-07-08
SOCRATE
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT05190445 2022-09-08
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Pieris Pharmaceuticals, Inc.
Phase 2 Active not recruiting